Homepage Top Section1

Under the terms of the deal, Stablix will use its platform to discover new heterobifunctional small molecule drug candidates (RESTORACs) against specified targets which are involved in several

The gene therapy is used for the treatment of inherited retinal disease (IRDs) caused by RPE65 mutations. Retina is impacted in patients who suffer from RPE65 mutation-associated IRDs and

Dewpoint’s discovery platform related to biomolecular condensates will be used to identify the drug candidates. The collaboration will enable combination of Novo Nordisk’s expertise in treating diabetes and

Selagine is a spin-out company from the University of Illinois at Chicago (UIC), while Grifols is a provider of plasma-derived medicines. A biologic drug, an immunoglobulin eye drop

Under the collaboration, both the companies will work together for further AI and machine learning-driven efforts in therapeutic development. The partnership aims to gather insights more precisely that

The once-daily oral medication FILSPARI has been designed to target two critical pathways selectively in the disease progression of IgAN (endothelin-1 and angiotensin II). It is said to

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of 5 August 2023. The drug is being evaluated

The optogenetic monotherapy has been developed to restore vision in blind patients. Nanoscope CEO Sulagna Bhattacharya said: “We are pleased to receive the FDA’s decision to grant Fast

Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments,